Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
ZINGO is an intradermal lidocaine hydrochloride monohydrate system approved in 2007 for rapid, needle-free local anesthesia. It delivers lidocaine via a spring-powered microprojection system to provide anesthesia within seconds, eliminating the need for traditional needle injections. The product is indicated for use prior to minor procedures requiring local anesthesia.
Product is in peak lifecycle stage with stable market position; team focus likely on market maintenance and operational efficiency rather than aggressive growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children
Working on ZINGO offers a stable, mature product career with predictable market dynamics and long patent protection until 2035. This is ideal for professionals seeking operational mastery and relationship-based selling in a niche, protected market rather than high-growth innovation.
Worked on ZINGO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo